Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mazurier

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|February 1, 1997
Mutations in the FVIII gene in seven families with mild haemophilia AC Mazurier, C Gaucher, S Jorieux, et al.
Pathologie-Biologie|December 1, 1975
[Contribution to the isolation and study of the molecular weight of human factor VIII]C Mazurier, A Parquet-Gernez, M Goudemand, et al.
Clinical and Laboratory Haematology|January 1, 1984
Cross-immunoelectrophoretic analysis of heparin and gelatin binding capacity of fibronectinC Mazurier, A Lefevre, M P Henon, et al.
Pathologie-Biologie|April 1, 1977
[HLA antigen and Willebrand's disease (author's transl)]J Goudemand, C Mazurier, A Parquet-Gernez, et al.
American Journal of Hematology|May 1, 1995
New variant of type II von Willebrand's disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding historyP Baillod, C Gaucher, B Affolter, et al.
Blood|May 1, 1991
The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor geneC Gaucher, S Jorieux, B Mercier, et al.
Blood|January 1, 1990
A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interactionC Mazurier, J Dieval, S Jorieux, et al.
European Journal of Haematology|July 1, 1989
In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's diseaseC Mazurier, C De Romeuf, A Parquet-Gernez, et al.
Thrombosis Research|September 15, 1984
Assay of factor IX antigen using an enzyme immuno assayA Parquet-Gernez, C Mazurier, J Amiral, et al.
European Journal of Haematology|August 26, 1998
A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand diseaseC Gaucher, H Uno, T Yamazaki, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|February 1, 1997
Mutations in the FVIII gene in seven families with mild haemophilia AC Mazurier, C Gaucher, S Jorieux, et al.
Pathologie-Biologie|December 1, 1975
[Contribution to the isolation and study of the molecular weight of human factor VIII]C Mazurier, A Parquet-Gernez, M Goudemand, et al.
Clinical and Laboratory Haematology|January 1, 1984
Cross-immunoelectrophoretic analysis of heparin and gelatin binding capacity of fibronectinC Mazurier, A Lefevre, M P Henon, et al.
Pathologie-Biologie|April 1, 1977
[HLA antigen and Willebrand's disease (author's transl)]J Goudemand, C Mazurier, A Parquet-Gernez, et al.
American Journal of Hematology|May 1, 1995
New variant of type II von Willebrand's disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding historyP Baillod, C Gaucher, B Affolter, et al.
Blood|May 1, 1991
The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor geneC Gaucher, S Jorieux, B Mercier, et al.
Blood|January 1, 1990
A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interactionC Mazurier, J Dieval, S Jorieux, et al.
European Journal of Haematology|July 1, 1989
In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's diseaseC Mazurier, C De Romeuf, A Parquet-Gernez, et al.
Thrombosis Research|September 15, 1984
Assay of factor IX antigen using an enzyme immuno assayA Parquet-Gernez, C Mazurier, J Amiral, et al.
European Journal of Haematology|August 26, 1998
A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand diseaseC Gaucher, H Uno, T Yamazaki, et al.
Pageof 13